Ongoing Trials

   • Prospective Ovarian Cancer: A Non-Interventional Prospective Study of the Accuracy of the
     Precision Therapeutics, Inc. ChemoResponse Assay in Patients with Recurrent epithelial
     ovarian, Peritoneal, OR Fallopian Tube cancer.

     Partner: Yale University

   • ChemoFx Registry: An observational, longitudinal, multi-center study examining outcomes
     associated with the use of the ChemoFx® Assay in solid tumor malignancies.
     For more information, send an email to registry@ptilabs.com.

Completed Trials

   • Retrospective Ovarian Cancer Outcomes: Study of progression-free survival in ChemoFx®
     Assay sensitive or resistant subjects with Stage III-IV primary or recurrent epithelial ovarian
     cancer or primary peritoneal carcinoma.

     Progression-free interval in ovarian cancer and predictive value of an ex vivo
     chemoresponse assay
     H. GALLION, WA. CHRISTOPHERSON, RL. COLEMAN, L. DEMARS, T. HERZOG, S.
     HOSFORD, H. SCHELLHAS, A. WELLS, BU SEVIN (2006)
     International Journal of Gynecological Cancer 16 (1), 194–201. doi:10.1111/j.1525-
     1438.2006.00301.x

   • Retrospective Ovarian Cancer Outcomes II: A Retrospective Treatment and Clinical
     Response Chart Review Study of Women with Ovarian Cancer tested with
     the ChemoFx® Assay.

     Partner: UPMC Magee Womens Hospital

     ChemoFx® assay is an independent predictor of response to platinum-based
     chemotherapy in primary ovarian cancer
     Holly Gallion, Amanda Nickles Fader, Joseph Kelly, Robert P. Edwards, John T. Comerci,
     Sarah L. Hosford, Helmut F. Schellhas Precision Therapeutic, Inc., Pittsburgh, PA;
     Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA;
     Atlanta Medical Center, Atlanta, GA; Tri-Health and Alliance Hospitals of Cincinnati
     and St. Elizabeth Medical Center of Northern Kentucky, Cincinnati, OH